IRIS
GENTILE, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.851
NA - Nord America 5.963
SA - Sud America 2.950
EU - Europa 2.601
AF - Africa 418
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 21.798
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.581
SG - Singapore 3.855
BR - Brasile 2.153
CN - Cina 1.920
VN - Vietnam 1.746
IT - Italia 1.051
BD - Bangladesh 526
HK - Hong Kong 401
FR - Francia 395
KR - Corea 315
AR - Argentina 287
DE - Germania 227
FI - Finlandia 183
IN - India 176
IQ - Iraq 156
MX - Messico 149
EC - Ecuador 126
GB - Regno Unito 118
RU - Federazione Russa 112
ZA - Sudafrica 108
NL - Olanda 107
CA - Canada 101
CO - Colombia 96
ID - Indonesia 88
PK - Pakistan 82
VE - Venezuela 80
TR - Turchia 73
MA - Marocco 71
AT - Austria 70
UA - Ucraina 70
CL - Cile 64
UZ - Uzbekistan 58
PY - Paraguay 54
DZ - Algeria 42
MY - Malesia 42
PH - Filippine 42
SA - Arabia Saudita 42
JO - Giordania 40
EG - Egitto 38
PL - Polonia 38
TN - Tunisia 36
ES - Italia 35
UY - Uruguay 35
NP - Nepal 29
JP - Giappone 28
PE - Perù 28
SE - Svezia 27
BO - Bolivia 26
KE - Kenya 26
KZ - Kazakistan 25
AE - Emirati Arabi Uniti 24
AZ - Azerbaigian 24
CR - Costa Rica 22
SN - Senegal 22
IL - Israele 21
CZ - Repubblica Ceca 20
KG - Kirghizistan 20
DO - Repubblica Dominicana 19
PA - Panama 18
ET - Etiopia 17
OM - Oman 17
AL - Albania 15
JM - Giamaica 15
BG - Bulgaria 14
GT - Guatemala 14
LB - Libano 14
HN - Honduras 13
PS - Palestinian Territory 13
TH - Thailandia 12
BA - Bosnia-Erzegovina 11
RO - Romania 11
RS - Serbia 11
QA - Qatar 10
NG - Nigeria 9
NI - Nicaragua 9
TT - Trinidad e Tobago 9
AO - Angola 8
IE - Irlanda 8
SK - Slovacchia (Repubblica Slovacca) 8
AU - Australia 7
HU - Ungheria 7
SY - Repubblica araba siriana 7
BE - Belgio 6
BH - Bahrain 6
BY - Bielorussia 6
CI - Costa d'Avorio 6
GE - Georgia 6
GR - Grecia 6
HR - Croazia 6
KH - Cambogia 6
KW - Kuwait 6
LT - Lituania 6
MU - Mauritius 5
CH - Svizzera 4
GA - Gabon 4
LY - Libia 4
MK - Macedonia 4
NO - Norvegia 4
PT - Portogallo 4
SC - Seychelles 4
Totale 21.720
Salva come PNG Salva come JPEG
Città #
Singapore 1.473
San Jose 1.176
Dallas 755
Boardman 650
Ho Chi Minh City 645
Ashburn 563
Council Bluffs 536
Hefei 510
Hong Kong 394
Hanoi 363
Beijing 329
Florence 321
Seoul 313
Lauterbourg 306
Shanghai 228
São Paulo 188
Helsinki 137
New York 127
Los Angeles 119
Da Nang 92
Haiphong 92
Santa Clara 90
Munich 83
Rio de Janeiro 72
Ogden 68
Rome 63
Guangzhou 60
Boydton 55
Amsterdam 51
Baghdad 51
Quito 51
Tashkent 50
Dhaka 49
Columbus 48
Milan 47
Sesto Fiorentino 47
Brasília 46
Noto 45
Vienna 45
Brooklyn 42
Biên Hòa 41
Belo Horizonte 39
Johannesburg 37
Amman 35
Buffalo 35
Frankfurt am Main 35
Mexico City 34
Montreal 34
Tianjin 33
Guayaquil 31
Rende 30
Warsaw 30
Chicago 29
Buenos Aires 28
Caracas 28
Wuhan 28
Curitiba 27
Hải Dương 27
Lahore 27
Montevideo 27
Orem 27
Porto Alegre 27
The Dalles 27
Asunción 26
Atlanta 25
Santiago 25
Thái Nguyên 25
Can Tho 24
Charlotte 24
Naples 24
Ninh Bình 24
Phoenix 24
Turku 24
Tokyo 23
Campinas 22
Dakar 22
Fortaleza 22
Bogotá 21
Chennai 21
Erbil 21
Lappeenranta 21
Nairobi 21
San Francisco 21
Stockholm 21
Washington 21
Kuala Lumpur 20
London 20
Baku 19
Chandler 19
Guarulhos 19
Nuremberg 19
Recife 19
Salvador 19
Bari 18
Cape Town 18
Casablanca 18
Falkenstein 18
Medellín 18
Santo André 18
Seattle 18
Totale 11.878
Salva come PNG Salva come JPEG
Nome #
Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study 180
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy 177
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 176
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 150
Vaccination in Multiple Myeloma: Challenges and Strategies 132
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 128
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 126
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 124
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 123
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 122
A novel phage display based platform for exosome diversity characterization 122
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 120
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 120
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 117
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 117
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 116
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 116
Momelotinib in myelofibrosis 115
Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay 113
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 112
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients 111
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 111
Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax 111
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 110
Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma 110
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 110
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 109
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 109
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 109
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing 109
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 108
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 108
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 107
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 106
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 105
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 105
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 105
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 105
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 103
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 103
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 103
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 102
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 102
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study 101
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 101
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 100
The role of corticosteroids in the current treatment paradigm for myelofibrosis 99
Belantamab mafodotin in multiple myeloma 98
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement 97
A progression-risk score to predict treatment free survival for early stage chronic lymphocytic leukemia patients. 94
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 93
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 93
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 93
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 93
Iron chelation therapy 92
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking? 92
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. 92
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 91
Teclistamab-cqyv in multiple myeloma 91
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 90
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement 90
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 89
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 89
Selinexor in multiple myeloma 89
Acalabrutinib in chronic lymphocytic leukemia 89
The use of ibrutinib before and after allogeneic stem cell transplantation 88
A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL) 88
Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma 88
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 87
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement 87
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. 87
Ibrutinib in patients over 80 with chronic lymphocytic leukemia: a multicenter Italian cohort 87
Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia Populations 87
Elotuzumab in multiple myeloma 87
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant 86
Cerebral pheohyphomycosis due to curvularia species 84
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 84
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 84
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study 84
Myelodysplastic syndromes with ring sideroblasts 83
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 82
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study 82
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 82
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice 82
Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms 82
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 82
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 82
A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide 82
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma 81
Ivosidenib in acute myeloid leukemia 81
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 80
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary Immune Thrombocytopenia: a randomised trial 80
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 80
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 79
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort 79
European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia 79
Tagraxofusp in myeloid malignancies 79
Avatrombopag for the Treatment of Immune Thrombocytopenia 78
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 78
Discovery of a Promising Hydroxyamino-Piperidine HDAC6 Inhibitor via Integrated Virtual Screening and Experimental Validation in Multiple Myeloma 77
Totale 10.021
Salva come PNG Salva come JPEG
Categoria #
all - tutte 129.670
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 129.670
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202224 0 2 0 0 2 0 0 6 1 1 5 7
2022/2023442 6 5 3 11 8 5 279 22 19 20 50 14
2023/20241.536 35 36 245 194 97 153 80 48 120 50 67 411
2024/20254.157 179 611 112 151 165 137 88 170 706 355 405 1.078
2025/202616.076 2.053 814 1.195 1.365 2.860 1.008 1.998 827 1.008 1.232 817 899
Totale 22.243